References of "MAGIS, Delphine"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailOccipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study
Magis, Delphine ULg; Allena, Marta; Bolla, Monica et al

in Lancet Neurology (2007), 6(4), 314-321

Background Drug-resistant chronic duster headache (drCCH) is a devastating disorder for which various destructive procedures have been tried unsuccessfully. Occipital nerve stimulation (ONS) is a new ... [more ▼]

Background Drug-resistant chronic duster headache (drCCH) is a devastating disorder for which various destructive procedures have been tried unsuccessfully. Occipital nerve stimulation (ONS) is a new, safe strategy for intractable headaches. We undertook a prospective pilot trial of ONS in drCCH to assess clinical efficacy and pain perception. Methods Eight patients with drCCH had a suboccipital neurostimulator implanted on the side of the headache and were asked to record details of frequency, intensity, and symptomatic treatment for their attacks in a diary before and after Continuous ONS. To detect changes in cephalic and extracephalic pain processing we measured electrical and pressure pain thresholds and the nociceptive blink reflex. Findings Two patients were pain free after a follow-up of 16 and 22 months; one of them still had occasional autonomic attacks. Three patients had around a 90% reduction in attack frequency. Two patients, one of whom had had the implant for only 3 months, had improvement of around 40%. Mean follow-up was 15.1 months (SD 9.5, range 3-22). Intensity of attacks tends to decrease earlier than frequency during ONS and, on average, is improved by 50% in remaining attacks. All but one patient were able to substantially reduce their preventive drug treatment. Interruption of ONS by switching off the stimulator or because of an empty battery was followed within days by recurrence and increase of attacks in all improved patients. ONS did not significantly modify pain thresholds. The amplitude of the nociceptive blink reflex increased with longer durations of ONS. There were no serious adverse events. Interpretation ONS could be an efficient treatment for drCCH and could be safer than deep hypothalamic stimulation. The delay of 2 months or more between implantation and significant clinical improvement suggests that the procedure ads via slow neuromodulatory processes at the level of upper brain stem or diencephalic centres. [less ▲]

Detailed reference viewed: 27 (2 ULg)
Full Text
Peer Reviewed
See detailInterictal habituation deficit of the nociceptive blink reflex: an endophenotypic marker for presymptomatic migraine?
Di Clemente, L.; Coppola, G.; Magis, Delphine ULg et al

in Brain : A Journal of Neurology (2007), 130(Pt 3), 765-770

Habituation of the nociception-specific blink reflex (nBR) is reduced interictally in migraine patients. This could be related to the habituation deficit of evoked cortical responses, a reproducible ... [more ▼]

Habituation of the nociception-specific blink reflex (nBR) is reduced interictally in migraine patients. This could be related to the habituation deficit of evoked cortical responses, a reproducible abnormality in migraine which has a familial character, or to central trigeminal sensitization due to repeated attacks. We compared nBR habituation in healthy volunteers devoid of personal or family history of migraine (HV), in migraine without aura patients (MO) and in healthy volunteers with a family history of migraine in first degree relatives (HV-F). We elicited the nBR by stimulating the right supraorbital region with a custom-built electrode in 16 MO between attacks, 15 HV and 14 HV-F. Habituation was measured as the percentage area-under-the-curve decrease in 10 consecutive blocks of five averaged rectified responses. nBR habituation was clearly reduced in MO and HV-F compared to HV. Percentage area under the curve decreased between the 1st and the 10th block by 55.01% in HV, 25.71% in MO (P = 0.001) and 26.73% in HV-F (P = 0.043). HV-F had the most pronounced abnormality with potentiation instead of habituation in the second block. We found a positive intraindividual correlation between attack frequency and habituation in MO (r = 0.621; P = 0.010). Migraine patients have interictally a deficient habituation of the nBR which is inversely related to attack frequency, suggesting that it is not due to trigeminal sensitization. Surprisingly, the most pronounced habituation deficit is found in asymptomatic individuals with a family history of migraine. Deficient nBR habituation could thus be a trait marker for the genetic predisposition to migraine. [less ▲]

Detailed reference viewed: 33 (2 ULg)
Full Text
Peer Reviewed
See detailA randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis
Magis, Delphine ULg; Ambrosini, Anna; Sandor, Peter et al

in Headache (2007), 47(1), 52-57

BACKGROUND: Impaired mitochondrial phosphorylation potential may play a role in migraine pathogenesis. Metabolic enhancers, such as riboflavin or coenzyme Q, are effective in migraine prophylaxis and ... [more ▼]

BACKGROUND: Impaired mitochondrial phosphorylation potential may play a role in migraine pathogenesis. Metabolic enhancers, such as riboflavin or coenzyme Q, are effective in migraine prophylaxis and quasi-devoid of adverse effects. Thioctic acid (-lipoic acid) is another substance known to enhance energy metabolism in mitochondria and to be beneficial in diabetic neuropathy. OBJECTIVE: After an open pilot study suggesting its therapeutic antimigraine potentials, we embarked therefore in a randomized controlled trial of thioctic acid (Thioctacid) in migraine prophylaxis steered by the Belgian Headache Society. METHODS: Five Belgian centers recruited 54 migraineurs (43 migraine without aura, 11 with aura; mean age 38 +/- 8 years; 7 males). After a 1-month single-blinded run-in period, 44 patients received either placebo (n = 18) or thioctic acid 600 mg p.o./day (n = 26) for 3 months. RESULTS: Statistical analysis was carried out on an intention-to-treat basis. Monthly attack frequency tended to be reduced between run-in and the 3rd month of treatment in the thioctic acid group compared to placebo (P= .06). The proportion of 50% responders was not significantly different between thioctic acid (30.8%) and placebo (27.8%). Within-group analyses showed a significant reduction of attack frequency (P= .005), headache days (P= .009), and headache severity (P= .03) in patients treated with thioctic acid for 3 months, while these outcome measures remained unchanged in the placebo group. No adverse effects were reported. For logistical reasons this trial was interrupted before the planned 80 patients were enrolled. CONCLUSION: Albeit underpowered, this study tends to indicate that thioctic acid may be beneficial in migraine prophylaxis. Before any firm conclusion can be drawn, however, a large multicenter trial is necessary. [less ▲]

Detailed reference viewed: 52 (3 ULg)
Full Text
Peer Reviewed
See detailTherapeutic armamentarium in neurology: the birth of a new era
Belachew, Shibeshih ULg; Magis, Delphine ULg; Lievens, Isabelle ULg et al

in Revue Médicale de Liège (2007), 62(5-6), 432-448

The field of neurology was long infamous for a lack of therapeutic options. How many of you have once thought: "Neurologists don't cure the disease, they admire it". But those days have passed into ... [more ▼]

The field of neurology was long infamous for a lack of therapeutic options. How many of you have once thought: "Neurologists don't cure the disease, they admire it". But those days have passed into history, and the field is now vibrant with new treatments and hope even for patients with the worst neurodegenerative diseases. We summarized in the present review the latest major advances in therapeutic principles and practice for some of the most frequent chronic neurological disorders such as headaches, epilepsy, multiple sclerosis, dementias, Parkinson's disease, sleep/wake disturbances and peripheral neuropathies. We cannot cure or prevent, but we can now halt or control symptoms and disease progression to provide physical and psychological relief, and a better quality of life for patients who suffer from these otherwise devastating neurological conditions. [less ▲]

Detailed reference viewed: 167 (15 ULg)
Full Text
Peer Reviewed
See detailLong-term depression of trigeminal nociceptive evoked potentials by supraorbital 1Hz electrical stimulations is deficient in migraineurs but not in tension-type headache patients
Magis, Delphine ULg; Bolla, M.; De Pasqua, Victor ULg et al

in Cephalalgia : An International Journal of Headache (2006, November), 26(11), 1386

Detailed reference viewed: 13 (6 ULg)
Full Text
Peer Reviewed
See detailLong term follow-up study of occipital nerve stimulation (ONS) for refractory chronic cluster headache: drastic change from short term outcome
Magis, Delphine ULg; Remacle, J. M.; Schoenen, Jean ULg

in Cephalalgia : An International Journal of Headache (2006, November), 26(11), 1398

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailLes céphalées par abus d'antalgiques et d'anti-migraineux
Fumal, Arnaud ULg; Magis, Delphine ULg; Schoenen, Jean ULg

in Revue Médicale de Liège (2006), 61(4), 217-22

Medication overuse headache (MOH) insidiously evolves from episodic migraine or tension-type headache because of overconsumption of analgesics, ergotamine or triptans. It affects 1-2% of the general ... [more ▼]

Medication overuse headache (MOH) insidiously evolves from episodic migraine or tension-type headache because of overconsumption of analgesics, ergotamine or triptans. It affects 1-2% of the general population, but 15-20% of patients attending specialized headache centers. The precise neurobiologic mechanisms underlying this complication of episodic headaches are not well understood. Abnormalities of central monoaminergic systems have been suggested and substance dependence is more frequent in personal and family histories of affected subjects. In a recent FDG-PET study of 16 migraineurs with MOH before and after analgesics withdrawal we found a persistent hypometabolism of the medial orbitofrontal cortex, comparable to the one described after withdrawal in substance abuse. The orbitofrontal cortex plays a pivotal role in drive, decision-making and drug dependence. We postulate that its hypoactivity predisposes certain migraineurs to MOH and to relapse after withdrawal. There is no unique management strategy for these patients, but medication withdrawal is a prerequisite for the effectiveness of preventive treatments and headache improvement. [less ▲]

Detailed reference viewed: 75 (4 ULg)
Full Text
Peer Reviewed
See detailHerbal medicines and vitamins
Schoenen, Jean ULg; Magis, Delphine ULg

in Lipton, R. B.; Bigal, M. E. (Eds.) Migraines and Other headache disorders (2006)

Detailed reference viewed: 17 (4 ULg)
Full Text
Peer Reviewed
See detailProton MRS findings in migraine patients during visual stimulation
da Silva, H. M.; Magis, Delphine ULg; Balteau, Evelyne ULg et al

in Cephalalgia : An International Journal of Headache (2005, December), 25(12), 1196

Detailed reference viewed: 19 (2 ULg)
Full Text
Peer Reviewed
See detailOccipital nerve stimulation in refractory chronic cluster headache: a pilot study of efficacy and mechanisms in five patients
Magis, Delphine ULg; Allena, M.; Vandenheede, Michel et al

in Cephalalgia : An International Journal of Headache (2005, December), 25(12), 1197

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailOccipital nerve stimulation in refractory chronic cluster headache: a pilot study of efficacy and mechanisms in five patients.
MAGIS, Delphine ULg; Allena, Marta; Vandenheede, Michel et al

in Cephalalgia : An International Journal of Headache (2005, October), 25

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailLack of habituation of visual evoked gamma band oscillations in migraine patients between attacks
Coppola, G.; Ambrosini, A.; Di Clemente, L. et al

in Cephalalgia : An International Journal of Headache (2005, October), 25(10), 885

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailThe vestibulo-collic reflex is smaller and lacks habituation in migraine patients between attacks
Allena, M.; Magis, Delphine ULg; da Silva, H. M. et al

in Cephalalgia : An International Journal of Headache (2005, October), 25(10), 874-875

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailTrigeminal nociceptive evoked potentials (TNEP) in migraine
Magis, Delphine ULg; Allena, Marta; De Pasqua, Victor ULg et al

in Cephalalgia : An International Journal of Headache (2005, October), 25(10), 875

Detailed reference viewed: 29 (7 ULg)
Full Text
Peer Reviewed
See detailSearch for a correlation between MTHFR C677T polymorphism and efficacy of riboflavin in migraine prophylaxis
Magis, Delphine ULg; Allena, Marta; da Silva, Hilton Mariano et al

in Cephalalgia : An International Journal of Headache (2005, October), 25(10), 864

Detailed reference viewed: 25 (2 ULg)
Full Text
Peer Reviewed
See detailEffects of nitroglycerin on the nociception specific blink reflex
Di Clemente, Laura; Magis, Delphine ULg; Coppola, Gianluca et al

in Cephalalgia : An International Journal of Headache (2005, October), 25(10), 888

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailMTHFR C677T polymorphism and susceptibility to migraine with aura
Magis, Delphine ULg; Coppola, Gianluca; Allena, Marta et al

in Cephalalgia : An International Journal of Headache (2005, October), 25(10), 863-864

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailEfficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial
Sandor, P. S.; Di Clemente, L.; Coppola, G. et al

in Neurology (2005), 64(4), 713-715

Riboflavin, which improves energy metabolism similarly to coenzyme Q10 (CoQ10), is effective in migraine prophylaxis. We compared CoQ10 (3 x 100 mg/day) and placebo in 42 migraine patients in a double ... [more ▼]

Riboflavin, which improves energy metabolism similarly to coenzyme Q10 (CoQ10), is effective in migraine prophylaxis. We compared CoQ10 (3 x 100 mg/day) and placebo in 42 migraine patients in a double-blind, randomized, placebo-controlled trial. CoQ10 was superior to placebo for attack-frequency, headache-days and days-with-nausea in the third treatment month and well tolerated; 50%-responder-rate for attack frequency was 14.4% for placebo and 47.6% for CoQ10 (number-needed-to-treat: 3). CoQ10 is efficacious and well tolerated. [less ▲]

Detailed reference viewed: 69 (3 ULg)
Peer Reviewed
See detailHeadache cases
MAGIS, Delphine ULg

Conference (2005)

Detailed reference viewed: 6 (0 ULg)